Clinical risk score for invasive fungal diseases in patients with hematological malignancies undergoing chemotherapy: China Assessment of Antifungal Therapy in Hematological Diseases (CAESAR) study
- 28 Downloads
Invasive fungal disease (IFD) is a major infectious complication in patients with hematological malignancies. In this study, we examined 4889 courses of chemotherapy in patients with hematological diseases to establish a training dataset (n = 3500) by simple random sampling to develop a weighted risk score for proven or probable IFD through multivariate regression, which included the following variables: male patients, induction chemotherapy for newly diagnosed or relapsed disease, neutropenia, neutropenia longer than 10 days, hypoalbuminemia, central-venous catheter, and history of IFD. The patients were classified into three groups, which had low (0–10, ~1.2%), intermediate (11–15, 6.4%), and high risk ( > 15, 17.5%) of IFD. In the validation set (n = 1389), the IFD incidences of the groups were ~1.4%, 5.0%, and 21.4%. In addition, we demonstrated that antifungal prophylaxis offered no benefits in low-risk patients, whereas benefits were documented in intermediate (2.1% vs. 6.6%, P = 0.007) and high-risk patients (8.4% vs. 23.3%, P = 0.007). To make the risk score applicable for clinical settings, a pre-chemo risk score that deleted all unpredictable factors before chemotherapy was established, and it confirmed that anti-fungal prophylaxis was beneficial in patients with intermediate and high risk of IFD. In conclusion, an objective, weighted risk score for IFD was developed, and it may be useful in guiding antifungal prophylaxis.
Keywordsinvasive fungal diseases hematological malignancies chemotherapy risk score prophylaxis
Unable to display preview. Download preview PDF.
Jiong Hu and Xiaojun Huang contributed to the conception and design of the study. Ling Wang, Ying Wang, and Jiong Hu interpreted the data and drafted the paper. Yuqian Sun, He Huang, Jing Chen, Jianyong Li, Jun Ma, Juan Li, Yingmin Liang, Jianmin Wang, Yan Li, Kang Yu, Jianda Hu, Jie Jin, Chun Wang, Depei Wu, and Yang Xiao were involved in the development of the methodology and participated in the analysis. All authors contributed in the writing, review, and revision of the article and final approval for submission.
The authors would like to thank the patients and investigators at each study site, without whom this study would not have been possible. The CAESAR study group investigators not listed as authors were as follows: Zhixiang Shen, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai; Waiyi Zou, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou; Jun Yang and Yu Cai, The First People’s Hospital of Shanghai, Shanghai; Yonghua Li, The General Hospital of Guangzhou Military Command of PLA, Guangzhou; Yongping Song and Yuewen Fu, Henan Tumor Hospital Affiliated to Zhengzhou University, Zhengzhou; Xudong Hu and Xingzhou Ren, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou; Huisheng Ai and Jianhui Qiao, Chinese PLA 307 Hospital, Beijing; Xianmin Song, Changhai Hospital of the Second Military Medical University, Shanghai; Hai Bai and Chunbang Wang, The General Hospital of Lanzhou Military Area, Lanzhou; Yongmin Tang and Heping Shen, Children’s Hospital of Zhejiang University Medical School, Hangzhou; Xiaoyan Zhang, Jiangsu Province Hospital, Nanjing; Xin Du and Chengwei Luo, Guangdong General Hospital, Guangzhou; Jian Ouyang and Yong Xu, Nanjing Drum Tower Hospital, Nanjing; Huo Tan and Runhui Zheng, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou; Ting Liu and Juan Xu, West China Hospital, Sichuan University, Chengdu; Jin Zhou and Liming Li, The First Hospital of Harbin Medical University, Harbin; Zhuogang Liu, Shengjing Hospital of China Medical University, Shenyang; Ping Zou and Yong You, Wuhan Union Hospital, Huazhong University of Science and Technology, Wuhan; Lin Liu and Li Wang, The First Affiliated Hospital of Chongqing Medical University, Chongqing; Ran Gao, The First Affiliated Hospital of China Medical University, Shenyang; Zhanxiang Liu, Chinese PLA General Hospital (301 Hospital), Beijing; Mangju Wang, The First Hospital of Peking University, Beijing; Guopan Yu, Nanfang Hospital, Nanfang Medical University, Guangzhou; Jun Wang, The First Affiliated Hospital of Soochow University, Suzhou; Guixin Zhang, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Tianjin; Xia Qin, Shanghai Children’s Medical Center, Shanghai; Liya Ma and Wangzhuo Xie, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, China.
This work was supported by Merck Sharp & Dohme (China), who sponsored the study. The support for the manuscript development was provided by Merck & Co., Inc. (Whitehouse Station, NJ, USA). The authors are grateful for the contribution made by Bo-Jing Cai (Merck & Co., Inc.) in the data management and statistical analysis.
- 2.Lewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: a 20-year autopsy study. Mycoses 2013; 56(6): 638–645CrossRefGoogle Scholar
- 3.Cornely OA, Maertens J,Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007; 356(4): 348–359CrossRefGoogle Scholar
- 4.Rijnders BJ, Cornelissen JJ, Slobbe L, Becker MJ, Doorduijn JK, Hop WC, Ruijgrok EJ, Löwenberg B, Vulto A, Lugtenburg PJ, de Marie S. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial. Clin Infect Dis 2008; 46(9): 1401–1408CrossRefGoogle Scholar
- 5.Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116(24): 5111–5118CrossRefGoogle Scholar
- 7.Mousset S, Buchheidt D, Heinz W, Ruhnke M, Cornely OA, Egerer G, Krüger W, Link H, Neumann S, Ostermann H, Panse J, Penack O, Rieger C, Schmidt-Hieber M, Silling G, Südhoff T, Ullmann AJ, Wolf HH, Maschmeyer G, Böhme A. Treatment of invasive fungal infections in cancer patients-updated recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2014; 93(1): 13–32CrossRefGoogle Scholar
- 8.Patterson TF, Thompson GR, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin Infect Dis 2016; 63(4): e1–e60CrossRefGoogle Scholar
- 9.Nucci M, Garnica M, Gloria AB, Lehugeur DS, Dias VC, Palma LC, Cappellano P, Fertrin KY, Carlesse F, Simões B, Bergamasco MD, Cunha CA, Seber A, Ribeiro MP, Queiroz-Telles F, Lee ML, Chauffaille ML, Silla L, de Souza CA, Colombo AL. Invasive fungal diseases in haematopoietic cell transplant recipients and in patients with acute myeloid leukaemia or myelodysplasia in Brazil. Clin Microbiol Infect 2013; 19(8): 745–751CrossRefGoogle Scholar
- 10.Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A. Invasive aspergillosis in patients with acute myeloid leukemia: a SEIFEM-2008 registry study. Haematologica 2010; 95(4): 644–650CrossRefGoogle Scholar
- 13.Caira M, Candoni A, Verga L, Busca A, Delia M, Nosari A, Caramatti C, Castagnola C, Cattaneo C, Fanci R, Chierichini A, Melillo L, Mitra ME, Picardi M, Potenza L, Salutari P, Vianelli N, Facchini L, Cesarini M, De Paolis MR, Di Blasi R, Farina F, Venditti A, Ferrari A, Garzia M, Gasbarrino C, Invernizzi R, Lessi F, Manna A, Martino B, Nadali G, Offidani M, Paris L, Pavone V, Rossi G, Spadea A, Specchia G, Trecarichi EM, Vacca A, Cesaro S, Perriello V, Aversa F, Tumbarello M, Pagano L; SEIFEM Group (Sorveglianza Epidemiologica Infezioni Fungine in Emopatie Maligne). Pre-chemotherapy risk factors for invasive fungal diseases: prospective analysis of 1,192 patients with newly diagnosed acute myeloid leukemia (SEIFEM 2010—a multicenter study). Haematologica 2015; 100(2): 284–292CrossRefGoogle Scholar
- 19.de Boer MG, Jolink H, Halkes CJ, van der Heiden PL, Kremer D, Falkenburg JH, van de Vosse E, van Dissel JT. Influence of polymorphisms in innate immunity genes on susceptibility to invasive aspergillosis after stem cell transplantation. PLoS One 2011; 6(4): e18403Google Scholar
- 20.Zaas AK, Liao G, Chien JW, Weinberg C, Shore D, Giles SS, Marr KA, Usuka J, Burch LH, Perera L, Perfect JR, Peltz G, Schwartz DA. Plasminogen alleles influence susceptibility to invasive aspergillosis. PLoS Genet 2008; 4(6): e1000101Google Scholar
- 21.Cristina ML, Sartini M, Spagnolo AM. Health care-acquired aspergillosis and air conditioning systems. J Prev Med Hyg 2009; 50(1): 3–8Google Scholar
- 22.Weber DJ, Peppercorn A, Miller MB, Sickbert-Benett E, Rutala WA. Preventing healthcare-associated Aspergillus infections: review of recent CDC/HICPAC recommendations. Med Mycol 2009; 47 (Suppl 1): S199–S209Google Scholar
- 23.Sun Y, Huang H, Chen J, Li J, Ma J, Li J, Liang Y, Wang J, Li Y, Yu K, Hu J, Jin J, Wang C, Wu D, Xiao Y, Huang X. Invasive fungal infection in patients receiving chemotherapy for hematological malignancy: a multicenter, prospective, observational study in China. Tumour Biol 2015; 36(2): 757–767CrossRefGoogle Scholar
- 24.Nivoix Y, Velten M, Letscher-Bru V, Moghaddam A, Natarajan-Amé S, Fohrer C, Lioure B, Bilger K, Lutun P, Marcellin L, Launoy A, Freys G, Bergerat JP, Herbrecht R. Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008; 47(9): 1176–1184CrossRefGoogle Scholar
- 25.Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, Pfaller M, Chang C, Webster K, Marr K. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis 2009; 48(3): 265–273CrossRefGoogle Scholar
- 26.Marr KA, Seidel K, Slavin MA, Bowden RA, Schoch HG, Flowers ME, Corey L, Boeckh M. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis-related death in allogeneic marrow transplant recipients: long-term followup of a randomized, placebo-controlled trial. Blood 2000; 96(6): 2055–2061Google Scholar
- 27.Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, Powderly WG, Silber JL, Horowitz H, Lichtin A, Wolff SN, Mangan KF, Silver SM, Weisdorf D, Ho WG, Gilbert G, Buell D. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326 (13): 845–851CrossRefGoogle Scholar
- 30.Glasmacher A, Prentice A, Gorschlüter M, Engelhart S, Hahn C, Djulbegovic B, Schmidt-Wolf IG. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients. J Clin Oncol 2003; 21(24): 4615–4626CrossRefGoogle Scholar
- 32.Pagano L, Caira M, Nosari A, Cattaneo C, Fanci R, Bonini A, Vianelli N, Garzia MG, Mancinelli M, Tosti ME, Tumbarello M, Viale P, Aversa F, Rossi G; HEMA e-Chart Group. The use and efficacy of empirical versus pre-emptive therapy in the management of fungal infections: the HEMA e-Chart Project. Haematologica 2011; 96(9): 1366–1370CrossRefGoogle Scholar
- 33.Groll AH, Castagnola E, Cesaro S, Dalle JH, Engelhard D, Hope W, Roilides E, Styczynski J,Warris A, Lehrnbecher T; Fourth European Conference on Infections in Leukaemia; Infectious Diseases Working Party of the European Group for Blood Marrow Transplantation (EBMT-IDWP); Infectious Diseases Group of the European Organisation for Research and Treatment of Cancer (EORTCIDG); International Immunocompromised Host Society (ICHS); European Leukaemia Net (ELN). Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014; 15(8): e327–e340CrossRefGoogle Scholar
- 34.Stanzani M, Lewis RE, Fiacchini M, Ricci P, Tumietto F, Viale P, Ambretti S, Baccarani M, Cavo M, Vianelli N. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS One 2013; 8(9): e75531Google Scholar
- 36.Cornet M, Levy V, Fleury L, Lortholary J, Barquins S, Coureul MH, Deliere E, Zittoun R, Brücker G, Bouvet A. Efficacy of prevention by high-efficiency particulate air filtration or laminar airflow against Aspergillus airborne contamination during hospital renovation. Infect Control Hosp Epidemiol 1999; 20(7): 508–513CrossRefGoogle Scholar
- 37.Berthelot P, Loulergue P, Raberin H, Turco M, Mounier C, Tran Manh Sung R, Lucht F, Pozzetto B, Guyotat D. Efficacy of environmental measures to decrease the risk of hospital-acquired aspergillosis in patients hospitalised in haematology wards. Clin Microbiol Infect 2006; 12(8): 738–744CrossRefGoogle Scholar